Literature DB >> 32110209

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation.

Asako Matsuda1, Yasuko Fuchimoto1, Sae Wada1, Takaaki Tanaka1, Tetsuya Takeguchi1, Sho Mitsumune1, Yuki Takigawa1, Yosuke Miyamoto1, Shinji Ozaki1, Norichika Iga2, Hideyuki Nishi2, Nobukazu Fujimoto3.   

Abstract

A 70-year-old woman underwent right upper lobectomy for adenocarcinoma of the lung (pT1bN2M0 stage IIIA). Five years after the surgery, lymph node recurrence was detected. Gefitinib was administered because epidermal growth factor (EGFR) exon 19 deletion mutation was detected in the previously resected surgical specimen. After a treatment of first-generation EGFR tyrosine kinase inhibitors, an FDG-PET/CT scan demonstrated abnormal FDG uptake in the pleura indicating pleural dissemination. Pleurocentesis revealed tumor cells in the pleural fluid; however, EGFR mutation testing failed due to inadequate tumor cellularity. Thoracoscopy under local anesthesia revealed multiple nodules on the parietal pleura. A biopsy specimen confirmed the diagnosis of lung adenocarcinoma with pleural dissemination and revealed EGFR exon 20-T790M mutation.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  EGFR-mutated non-small cell lung cancer; Osimertinib; Rebiopsy; T790M; Thoracoscopy

Year:  2019        PMID: 32110209      PMCID: PMC7036578          DOI: 10.1159/000504932

Source DB:  PubMed          Journal:  Case Rep Oncol        ISSN: 1662-6575


  11 in total

1.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

Review 2.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Authors:  Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

Review 3.  Medical thoracoscopy and its evolving role in the diagnosis and treatment of pleural disease.

Authors:  Vivek Murthy; Jamie L Bessich
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

4.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

Review 5.  Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

Authors:  Kim-Son H Nguyen; Susumu Kobayashi; Daniel B Costa
Journal:  Clin Lung Cancer       Date:  2009-07       Impact factor: 4.785

6.  Effectiveness and safety of diagnostic flexi-rigid thoracoscopy in differentiating exudative pleural effusion of unknown etiology: a retrospective study of 215 patients.

Authors:  Bao-An Gao; Gang Zhou; Li Guan; Ling-Yun Zhang; Guang-Ming Xiang
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

7.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

Authors:  Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

8.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

9.  Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.

Authors:  Takahisa Kawamura; Hirotsugu Kenmotsu; Tetsuhiko Taira; Shota Omori; Kazuhisa Nakashima; Kazushige Wakuda; Akira Ono; Tateaki Naito; Haruyasu Murakami; Keita Mori; Takashi Nakajima; Yasuhisa Ohde; Masahiro Endo; Toshiaki Takahashi
Journal:  Cancer Sci       Date:  2016-06-21       Impact factor: 6.716

10.  Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer.

Authors:  Eiki Ichihara; Katsuyuki Hotta; Toshio Kubo; Tsukasa Higashionna; Kiichiro Ninomiya; Kadoaki Ohashi; Masahiro Tabata; Yoshinobu Maeda; Katsuyuki Kiura
Journal:  Oncotarget       Date:  2018-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.